BRG01

DB18173InvestigationalCell transplant therapies

BRG01 is a genetically modified autologous CAR-T cell therapy under investigation for the treatment of nasopharyngeal carcinoma.

Mechanism: Pharmacologically active on Latent membrane protein 1
Curator reviewed
Code names: BRG-01

Resolves to

Targets

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with BRG01, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.